The acquisition of B. Braun Medical AG Switzerland’s manufacturing assets will advance the launch of personalized skin regeneration therapy, EpiDex, says Healiva. Healiva, a firm that delivers medicine for individuals with chronic and acute wounds, has acquired pharmaceutical device company, B.Braun’s, manufacturing assets for an undisclosed fee. The acquisition includes a qualified cell bank, which Healiva says is vital for the GMP-compliant production of its first cell therapy product, EpiDex. According to Healiva, the acquisition of a qualified fibroblast cell…